Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOX + Bevacizumab for Resectable Colorectal Liver Metastases
NCT00118105Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2006
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by SWOG Cancer Research Network. Primary endpoints: Proportion of patients with R0 resection after treatment, Probability of nonprogression at 12 weeks and 5 more. Planned start Nov 2006; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00118105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118105.